US EditionNew leukaemia treatment hailed as 'milestone' in cancer management
- The Flair trial, led by Dr Talha Munir at Leeds, studied 786 untreated chronic lymphocytic leukaemia patients across 96 UK cancer centres.
- Researchers sought to assess if two targeted drugs, ibrutinib and venetoclax, could outperform standard chemotherapy by personalizing treatment based on cancer response.
- After two years, 66% of patients receiving the new treatment showed no trace of cancer in their bone marrow, compared to 48% of those treated with chemotherapy and none treated with ibrutinib alone.
- Dr Munir called the trial a “milestone” and stated chemotherapy-free treatment can be both more effective and better tolerated for patients.
- The results suggest a shift towards kinder, personalized therapies for CLL, potentially improving survival and quality of life for thousands diagnosed annually in the UK.
Insights by Ground AI
Does this summary seem wrong?
15 Articles
15 Articles
All
Left
4
Center
4
Right
Oxford MailReposted by 
thisisoxfordshire.co.uk
thisisoxfordshire.co.ukOxford researchers make breakthrough in treatment of aggressive leukaemia
Researchers at Oxford University have uncovered a potential new therapeutic target in a particularly aggressive and hard-to-treat form of leukaemia.
·Oxford, United Kingdom
Read Full Article
Evening Standard+4 Reposted by 4 other sources
New leukaemia treatment hailed as ‘milestone’ for patients
After five years, 94% of patients were alive, with no disease progression.
·London, United Kingdom
Read Full Article
Coverage Details
Total News Sources15
Leaning Left4Leaning Right0Center4Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
